# Daiichi Sankyo (Germany)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/daiichi-sankyo-germany/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 36 |
| Citations | 251,610 |
| City | Munich |
| Country | DE |
| Description | Daiichi Sankyo (Germany) is a research organisation in Munich, DE. OpenAlex records 3,191 works and 251,610 citations for it. 951 researchers list it as their most recent affiliation. |
| Homepage | https://www.daiichi-sankyo.eu/ |
| OpenAlex ID | https://openalex.org/I179904914 |
| Researchers | 951 |
| ROR ID | https://ror.org/01qhj1g70 |
| Type | company |
| Wikidata ID | https://www.wikidata.org/wiki/Q669441 |
| Works | 3,191 |

## University papers

Showing 12 of 16.

- [Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial](https://scholariq.org/papers/treatment-with-two-different-doses-of-sonidegib-in-patients-with-locally/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study](https://scholariq.org/papers/long-term-efficacy-and-safety-of-sonidegib-in-patients-with-advanced-basal-cell/)
- [Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study](https://scholariq.org/papers/long-term-efficacy-and-safety-of-sonidegib-in-patients-with-locally-advanced-and/)
- [Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth](https://scholariq.org/papers/prevention-of-dietary-fat-fueled-ketogenesis-attenuates-braf-v600e-tumor-growth/)
- [Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)](https://scholariq.org/papers/treatment-with-trastuzumab-deruxtecan-in-patients-with-her2-positive-breast/)
- [Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan](https://scholariq.org/papers/efficacy-and-safety-of-memantine-in-patients-with-moderate-to-severe-alzheimer-s/)
- [Combination of GSH Trapping and Time-Dependent Inhibition Assays as a Predictive Method of Drugs Generating Highly Reactive Metabolites](https://scholariq.org/papers/combination-of-gsh-trapping-and-time-dependent-inhibition-assays-as-a-predictive/)
- [Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study](https://scholariq.org/papers/efficacy-and-safety-of-add-on-mirogabalin-to-nsaids-in-lumbar-spinal-stenosis/)
- [Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study)](https://scholariq.org/papers/efficacy-and-safety-of-mirogabalin-for-chemotherapy-induced-peripheral/)
- [Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance](https://scholariq.org/papers/safety-of-the-long-acting-neuraminidase-inhibitor-laninamivir-octanoate-hydrate/)
- [Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study](https://scholariq.org/papers/efficacy-and-safety-of-gpr119-agonist-ds-8500a-in-japanese-patients-with-type-2/)

## University researchers

- [Kazuhito Shiosakai](https://scholariq.org/researchers/kazuhito-shiosakai/)

## University top topics

Showing 8 of 25.

- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Microbial Natural Products and Biosynthesis](https://scholariq.org/topics/microbial-natural-products-and-biosynthesis/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.